acquired
Stage
About
MediSix Therapeutics is a Singapore-based company developing immune cell engineering and innovative T-cell therapies using its proprietary Protein Expression Blocker (PEBL) technology platform to treat cancer and autoimmune diseases.
Explore MediSix Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.